The pharmacoepidemiological analysis of the influenza pharmacotherapy in Ukraine
Keywords:flu, pharmacoepidemiological analysis, antiviral drugs
Influenza and other acute respiratory viral infections (ARIs) are the most common among human diseases that require timely medical attention and treatment with the most effective drugs.
The aim of the study is pharmacoepidemiological analysis of drugs for the treatment of influenza registered in Ukraine.
Materials and methods of research. The study was based on data from the State Register of Medicines of Ukraine, information on the results of the epidemic season of influenza and acute respiratory infections of the Center for Public Health of the Ministry of Health of Ukraine, declared drugs under the International Nonproprietary or Common Name in Ukraine as of January 2021. Methods: retrospective, descriptive and frequency analyzes.
Results and discussion. A pharmacoepidemiological analysis of influenza drugs in Ukraine was conducted. It was found that the incidence of influenza and SARS during the study period decreased by 3.1% of the total population. Fatalities due to influenza and SARS increased by 41 cases during the study period, which may be related to the coronavirus pandemic. According to the results of a marketing study of antiviral drugs, it was found that the largest share in the structure of registered trade names are interferons (11 trade names).
Conclusions. The analysis of the market showed that among the antiviral drugs registered in Ukraine for the studied period the dominance of domestic drugs is noted - 54% (respectively of foreign origin - 46%).
Analysis of the distribution of domestic analogues of antiviral drugs by manufacturers found that the largest (5 and 4 TN) belongs to LLC "Research and production company" Interpharmbiotek and FZ "Biopharma" Ltd., Ukraine, Bila Tserkva.
Key words: influenza; pharmacoepidemiological analysis; antiviral drugs
Andreychin M.A., Kopcha V.S., Moskalyuk V.D., Girina O.M., Yosik Ya.I. Udoskonalennya likuvannya hvorih na grip ta inshi GRVI // Infektsiyni hvorobi. – 2013. – # 2, T. 72. – S. 12-19.
Nemchenko A. S. Marketingoviy analiz rinku protivirusnih likiv vid gripu / A. S. Nemchenko, L. S. Simonyan, O. A. Nemchenko // Profesiyniy menedzhment v suchasnih umovah rozvitku rinku : materiali dop. IV nauk.-prakt. konf. z mizhnar. uchastyu, m. Harkiv, 3 listop. 2015 r. – H., 2015. – S. 179-181.
Sheptak T. I. Analiz protivirusnih likarskih zasobiv na farmatsevtichnomu rinku, priznachenih dlya farmakoterapiyi GRVI / T. I. Sheptak, O. V. Tkachova // Tehnologichni ta biofarmatsevtichni aspekti stvorennya likarskih preparativ riznoyi napravlenosti dIyi : materiali III Mizhnar. nauk.-prakt. Internet-konferentsiyi, m. Harkiv, 14-15 list. 2017 r. - Harkiv : NFaU, 2017. - S. 210-211
Tkachova O.V., Silaev A.O., Sheptak T.I. Analiz spozhivannya protivirusnih likarskih zasobiv na farmatsevtichnomu rinku Ukrayini, yaki vikoristovuyutsya dlya farmakoterapiyi hvorih na gostri respiratorni virusni infektsiyi / Ukraïns’kij bìofarmacevtičnij žurnal, 2018. - № 1 (54). – С. 36-38.
Serhii O. S. Serhii H. U. Tetiana A. A. A cost minimization analysis of α2b-interferon supplementation in complex pharmacotherapy of rotavirus infection in newborns / Čes. slov. Farm. 2020; 69, 83–89.
Anna A. G., Roman A. B., Yana R. V., Anastasia A. B. Modern approaches to pharmacotherapy of Community-Acquired Pneumonia / Research Results in Pharmacology 6(4): 77–84.
Derzhavniy reestr likarskih zasobiv [elektronniy resurs]: [rezhim dostupu]. - Electronic data. - Access: http://www.drlz.com.ua/ibp/ddsite.nsf/all/shlist?opendocument
Pidsumki epidemichnih sezoniv gripu ta gostrih respiratornih infektsiy Tsentru gromadskogo zdorov’ya MOZ Ukrayini. Rezhim dostupu:
Dani derzhavnogo reestru optovo-vidpusknih tsin stanom na 21.01.2021 [elektronniy resurs]: [rezhim dostupu]. - Electronic data. - Access: https://pharmbase.com.ua/ru/optovye-predlozheniya
Derzhavniy formulyar likarskih zasobiv, 2020 (12 vipusk) / Rezhim dostupa:
Copyright (c) 2021 National University of Pharmacy
This work is licensed under a Creative Commons Attribution 4.0 International License.Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).